|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3 Pt 1
|
|
pubmed:dateCreated |
2006-2-9
|
|
pubmed:abstractText |
Mesothelin is an emerging marker for cancer diagnosis and target-based therapy, yet relatively little is known about the clinical significance of mesothelin expression in tumors. In this study, we correlate mesothelin immunoreactivity to clinicopathologic features in ovarian serous carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
827-31
|
|
pubmed:dateRevised |
2011-10-26
|
|
pubmed:meshHeading |
pubmed-meshheading:16467095-Antibodies, Monoclonal,
pubmed-meshheading:16467095-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16467095-Cell Differentiation,
pubmed-meshheading:16467095-Cystadenocarcinoma, Serous,
pubmed-meshheading:16467095-Drug Resistance, Neoplasm,
pubmed-meshheading:16467095-Female,
pubmed-meshheading:16467095-GPI-Linked Proteins,
pubmed-meshheading:16467095-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:16467095-Humans,
pubmed-meshheading:16467095-Immunohistochemistry,
pubmed-meshheading:16467095-Membrane Glycoproteins,
pubmed-meshheading:16467095-Ovarian Neoplasms,
pubmed-meshheading:16467095-Retrospective Studies,
pubmed-meshheading:16467095-Survival Rate
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
|
|
pubmed:affiliation |
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
In Vitro
|
